Researchers at a WuXi AppTec site in Philadelphia. (Credit: WuXi)
WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down
It’s hard to disentangle WuXi AppTec’s rise from China’s. Over the last two decades, the Shanghai-based company grew from nothing into a research superstore for the world’s biopharma companies.
But as tensions between the US and China have grown, so have doubts about WuXi’s future. It has become so intertwined with US drugmakers and biotech startups that it’s now seen as a risk, both by some in Congress and by companies that fear getting caught up in a geopolitical struggle over WuXi’s alleged ties to the Chinese military.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
